| 83.88 -0.439 (-0.52%) | 02-20 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 100.35 | 1-year : | 117.21 |
| Resists | First : | 85.91 | Second : | 100.35 |
| Pivot price | 82.19 |
|||
| Supports | First : | 81.73 | Second : | 79.15 |
| MAs | MA(5) : | 83.09 |
MA(20) : | 82.43  |
| MA(100) : | 77.83 |
MA(250) : | 67.66 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 97.1 |
D(3) : | 84.6 |
| RSI | RSI(14): 57.8 |
|||
| 52-week | High : | 85.91 | Low : | 48.65 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BBP ] has closed below upper band by 15.9%. Bollinger Bands are 0.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 84.06 - 84.48 | 84.48 - 84.75 |
| Low: | 82.17 - 82.74 | 82.74 - 83.11 |
| Close: | 83.06 - 83.92 | 83.92 - 84.48 |
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.
Wed, 18 Feb 2026
(BBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Tue, 17 Feb 2026
Why Is ImmunityBio Stock Gaining Tuesday? - Benzinga
Sat, 07 Feb 2026
(BBP) Risk Channels and Responsive Allocation - Stock Traders Daily
Thu, 30 Oct 2025
Biotech ETFs Hovering Around a 52-Week: Here's Why - Nasdaq
Mon, 20 Oct 2025
Biotech ETFs Bounce Back in 2025: Here's Why - Nasdaq
Thu, 04 Jul 2024
SBIO, XBI, or BBP: Which is the Best Biotech ETF, According to Analysts? - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|